Halozyme Therapeutics Inc

NASDAQ:HALOUnited States

Halozyme Therapeutics, Inc. is a biopharmaceutical company advancing disruptive solutions to improve patient experiences and outcomes for emerging and established therapies. The Company’s ENHANZE drug delivery technology with the proprietary enzyme rHuPH20, its commercially validated solution is used to facilitate the subcutaneous (SC) delivery of injected drugs and fluids, with a focus on reducing treatment burden for patients. It also develops, manufactures, and commercializes, for itself or with partners, drug-device combination products using its advanced auto-injector technologies. The Company has two commercial proprietary products, Hylenex and XYOSTED, partnered commercial products and ongoing product development programs with several pharmaceutical companies. It markets and sells Hylenex recombinant, which is a formulation of rHuPH20. It markets and sells its proprietary product XYOSTED for SC administration of testosterone replacement therapy (TRT) in adult males.

Contact Information

Headquarters

12390 EL CAMINO REALSAN DIEGO, CA, United States 92130

Phone

858-794-8889

Fax

302-655-5049

Executives

Independent Chairman of the Board

Jeffrey Henderson

President, Chief Executive Officer, Director

Helen Torley

Chief Financial Officer, Senior Vice President

Nicole Labrosse

Senior Vice President, Chief Technical Officer

Michael Labarre

Senior Vice President, Chief Compliance Officer, General Counsel, Secretary

Mark Snyder